trandolapril-ratiopharm 4 mg
ratiopharm gmbh, nemecko - trandolapril - 58 - hypotensiva
trandolapril-ratiopharm 2 mg
ratiopharm gmbh, nemecko - trandolapril - 58 - hypotensiva
soliris
alexion europe sas - eculizumab - hemoglobinúria, paroxysmálna - imunosupresíva - soliris je indikovaný u dospelých a detí na liečbu:paroxyzmálna nočné haemoglobinuria (pnh). dôkazy z klinických výhodou je preukázaná u pacientov s haemolysis s klinický príznak(s) svedčí o vysokej aktivity ochorenia, bez ohľadu na transfúziu históriu (pozri časť 5. atypické haemolytic-uremickým syndrómom (zariadenia). soliris je indikovaný u dospelých na liečbu:Žiaruvzdorné generalizované myasthenia gravis (gmg) u pacientov, ktorí sú anti-acetylcholínové receptory (achr) protilátky-pozitívne (pozri časť 5. neuromyelitis optica spektrum poruchy (nmosd) u pacientov, ktorí sú anti-aquaporin-4 (aqp4) protilátky-pozitívne s relapsujúcou priebeh ochorenia.
aqumeldi
proveca pharma limited - enalapril (maleate) - zástava srdca - Činidlá pôsobiace na systém renín-angiotenzín - treatment of heart failure.
ultomiris
alexion europe sas - ravulizumab - hemoglobinúria, paroxysmálna - selektívne imunosupresíva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
enalapril vitabalans 5 mg tablety
vitabalans oy, fínsko - enalapril - 58 - hypotensiva
enalapril vitabalans 10 mg tablety
vitabalans oy, fínsko - enalapril - 58 - hypotensiva
enalapril vitabalans 20 mg tablety
vitabalans oy, fínsko - enalapril - 58 - hypotensiva
trandolapril mylan 2 mg
mylan ireland limited, Írsko - trandolapril - 58 - hypotensiva
trandolapril mylan 4 mg
mylan ireland limited, Írsko - trandolapril - 58 - hypotensiva